ASND

Ascendis Pharma A/S

NasdaqGSUSDEQUITY DELAYED

253.29

▼ 1.52 (0.60%)

MARKET · —

Price

Open

255.01

Prev close

254.81

Day high

257.89

Day low

252.87

Volume

363.76K

Market cap

—

P/E (TTM)

—

52W range

186.05 – 282.15

Trailing performance

Price return · vs SPY

Returnvs SPY

+1.93% +3.3%

+0.25% -3.5%

+2.34% -0.8%

+12.57% +1.5%

YTD

+18.78% +6.5%

+31.38% +11.4%

+181.75% +107.6%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

252.43

+0.34% from price

SMA 20

250.84

+0.98% from price

SMA 50

252.20

+0.43% from price

SMA 100

242.14

+4.60% from price

SMA 200

229.70

+10.27% from price

EMA 12

252.33

+0.38% from price

EMA 26

252.12

+0.46% from price

EMA 50

249.68

+1.45% from price

RSI (14)

51.3

Neutral

MACD (12,26,9)

0.21

Hist 0.42

ATR (14)

8.17

3.23% of price

Realised vol 30D

27.3%

Annualised

Bollinger upper

260.09

20, 2σ

Bollinger lower

241.58

20, 2σ

50 / 200 cross

Golden

252.20 vs 229.70

Trend bias

Above 200

+10.27%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.26

Less volatile than market

Correlation to SPY

0.09

Largely independent

Realised vol 30D

27.3%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-17.6%

Peak to trough

Max drawdown 5Y

-60.5%

Peak to trough

ATR 14

8.17

3.23% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 253.29

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ASND · links out to the publisher

Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine Insider Monkey · 22h ago Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript Motley Fool · 2d ago Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress? Simply Wall St. · 2d ago Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced? Simply Wall St. · 2d ago BMO Capital Initiates Ascendis Pharma at Outperform MT Newswires · 3d ago Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients GlobeNewswire · 4d ago Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says MT Newswires · 8d ago RBC Adjusts PT on Ascendis Pharma to $290 From $280, Maintains Outperform Speculative Risk Rating MT Newswires · 8d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.